BROMFENAC |
ISV-303 |
YELLOX |
PROLENSA® |
2-AMINO-3-(4-BROMOBENZOYL)BENZENEACETIC ACID |
XIBROM® |
[2-AMINO-3-(4-BROMO-BENZOYL)-PHENYL]-ACETIC ACID |
BROMFENACO |
AHR-10282B |
BROMDAY® |
BROMFENACUM |
rxcui:19737 |
drugbank:00963 |
pubchem.compound:60726 |
chemidplus:91714-94-2 |
chembl:CHEMBL1077 |
Drug Class | anti-inflammatory agents, non-steroidal |
Year of Approval | 1997 |
FDA Approval | approved |
Drug Class | Small Molecule |
Drug Indications | opthalmological agent,NSAID |
inhibitor (inhibitory) |
Trial Name | Bromfenac |
Novel drug target | Established target |
Trial Name | ISV-101 |
inhibitor (inhibitory) |
Trial Name | Bromfenac |
Novel drug target | Established target |
Trial Name | ISV-101 |
BROMFENAC | Primary Drug Name |
Year of Approval | 1997 |
Drug Class | anti-inflammatory agents, non-steroidal |
Drug Indications | opthalmological agent,NSAID |
Drug Class | Small Molecule |
FDA Approval | approved |
D0U1OM | TTD Drug ID |